Form 4: Harvard Bioscience Director Reports Stock Award

Harvard Bioscience Director William Snider reported the acquisition of 16,556 restricted stock units.

Summary

• Director William Snider of Harvard Bioscience, Inc. has reported a transaction involving restricted stock units.
• The transaction, dated June 9, 2026, involved the acquisition of 16,556 restricted stock units (RSUs).
• These RSUs are set to vest in full either immediately prior to the company's next annual meeting or one year from the grant date, whichever comes first.
• Following this award, Snider's total beneficial ownership includes 48,556 shares.
• This total ownership comprises the newly awarded RSUs, previously purchased shares (12,525 on March 16, 2026, and 8,475 on March 17, 2026), and 11,000 additional RSUs vesting on December 17, 2026.
• The filing also notes a 10-for-1 reverse stock split that occurred on March 13, 2026, which adjusted the reporting of previously held RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it represents a routine disclosure of stock awards to a director rather than a significant financial event or strategic shift.

Positives

• Director William Snider has received a new award of 16,556 restricted stock units, indicating continued equity incentive for key management.
• The total beneficial ownership of 48,556 shares suggests a significant stake held by the director.
• The filing confirms previous share purchases by the director, demonstrating personal investment in the company.

Risks

• The vesting of the restricted stock units is contingent on future events (company's next annual meeting or one year from grant date), introducing a time-based risk for the director's full ownership.
• The reverse stock split mentioned could be an indicator of past stock price performance issues, though not explicitly stated as a risk in this filing.

Future Outlook

The restricted stock units awarded to William Snider will vest in full either immediately prior to the Company's next annual meeting or one year from the date of grant, whichever is earlier.

Industry Context

StockSavvy.ai notes that the reporting of stock awards and beneficial ownership by directors is a standard disclosure practice under SEC regulations, providing transparency to investors regarding insider holdings and compensation structures within the biotechnology sector.

Stakeholder Impact

• Shareholders gain insight into director compensation and potential insider stock accumulation.
• Employees may view director equity awards as a sign of management commitment and alignment with company performance.

Next Steps

• Vesting of 16,556 restricted stock units prior to the next annual meeting or within one year of the grant date.
• Vesting of 11,000 restricted stock units on December 17, 2026.

Key Dates

Keywords

Harvard Bioscience, HBIO, Form 4, SEC Filing, Stock Award, Restricted Stock Units, Director, Beneficial Ownership, Equity Incentive, Reverse Stock Split